Print Page  Close Window

SEC Filings

S-1
VITAE PHARMACEUTICALS, INC filed this Form S-1 on 08/12/2014
Entire Document
 

Table of Contents

        The vesting schedule applicable to each outstanding award is described in the footnotes to the table below.

 
  Option Awards   Stock Awards  
Name
  Number of
Securities
Underlying
Unexercised
Options
Exercisable
(#)
  Number of
Securities
Underlying
Unexercised
Options
Unexercisable
(#)
  Equity Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised,
Unearned
Options (#)
  Option
Exercise
Price ($)
  Option
Expiration
Date
  Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)
  Market
Value of
Shares or
Units of
Stock That
Have Not
Vested
($)(1)
 

Jeffrey S. Hatfield

    186,667 (2)             $ 0.05     3/14/2015              

    186,666 (3)             $ 0.05     3/14/2015              

    712,598 (4)             $ 0.05     3/14/2015              

    128,459 (5)             $ 0.15     3/28/2016              

    610,361 (6)             $ 0.15     3/28/2016              

    389,639 (7)             $ 0.15     3/28/2016              

    600,000 (8)             $ 0.15     7/24/2017              

    700,000 (9)             $ 0.15     9/25/2017              

    143,636 (10)             $ 0.17     1/29/2018              

    480,000 (11)             $ 0.17     1/20/2019              

    237,380 (12)             $ 0.30     3/23/2020              

                3,100,000 (13) $ 0.31     3/22/2021              

                                  9,000,000 (14)      

Richard Gregg, M.D. 

   
3,850,000

(15)
           
$

0.17
   
3/25/2018
             

    315,000 (11)             $ 0.17     1/20/2019              

    155,780 (12)             $ 0.30     3/23/2020              

                1,180,000 (13) $ 0.31     3/22/2021              

Tina Fiumenero*

   
1,150,000

(16)
 
   
 
$

0.15
   
3/28/2016
             

    561,000 (8)   39,000 (17)       $ 0.15     7/24/2017              

    62,733 (18)         $ 0.17     1/29/2018              

    500,000 (19)         $ 0.17     9/23/2018              

    251,786 (11)         $ 0.17     1/20/2019              

    124,520 (12)         $ 0.30     3/23/2020              

            450,000 (13) $ 0.31     3/22/2021              

*
Pursuant to her stock option agreements with us, the vested portion of Ms. Fiumenero's options expire on the date that is three months following the date on which her employment with us terminated. The unvested portion of her options expired immediately upon the termination of her employment with us.

(1)
Market value is based on the fair market value of our common stock on December 31, 2013. As there was no public market for our common stock on December 31, 2013, we have assumed that the fair market value on December 31, 2013 was $            , which represents the midpoint of the range set forth on the cover page of this prospectus.

(2)
The option vested in substantially equal installments over 12 months of service following February 1, 2005.

(3)
The option vested in equal installments over 6 months of service following July 1, 2005, with the first five installments occurring monthly after February 1, 2005, and the last installment occurring on January 1, 2006.

(4)
The option vested in substantially equal installments over 12 months of service following March 23, 2008.

(5)
The option vested in substantially equal installments over 12 months of service following February 15, 2006.

(6)
47,858 of the option shares vested on March 29, 2007, with the remaining option shares vesting in substantially equal monthly installments over 27 months of service following December 30, 2007.

(7)
202,142 of the option shares vested on March 29, 2007, with the remaining option shares vesting in equal monthly installments over 9 months of service thereafter.

(8)
Represents the vested portion of a performance-based option granted on July 25, 2007.

(9)
The option vested in equal monthly installments over 48 months of service following October 2, 2008.

129